Last reviewed · How we verify
Linagliptin 10 mg
Linagliptin 10 mg, marketed by Alexandria University, is a DPP-4 inhibitor with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and long-term patent protection. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Linagliptin 10 mg |
|---|---|
| Also known as | Linagliptin |
| Sponsor | Alexandria University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Glycemic Variability of Combination Therapies in T2DM (PHASE4)
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (PHASE1, PHASE2)
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (PHASE1, PHASE2)
- Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus (PHASE3)
- The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients . (PHASE4)
- To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions. (PHASE1)
- New Triple Therapy in Newly Diagnosed Type 2 Diabetes (PHASE3)
- Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Linagliptin 10 mg CI brief — competitive landscape report
- Linagliptin 10 mg updates RSS · CI watch RSS
- Alexandria University portfolio CI